Claims
- 1. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula:
- 2. The compound of claim 1, wherein Ar1 is phenyl, thiophenyl, furanyl, naphthyl, isoxazolyl, indolyl, pyridyl, pyrimidyl, 2-piperidone, 3-piperidone, or 4-piperidone.
- 3. The compound of claim 2, wherein Ar1 is 4-chlorophenyl, 4-fluorophenyl, 3-methylphenyl, 3-fluorophenyl, 3-chlorophenyl, 3-(MeS)-phenyl sulfide, 3-(MeSO2)-phenyl, or 3-methyl-4-flurophenyl.
- 4. The compound of claim 1, wherein NR2R3 is NH2, piperidinyl, pyrrolidinyl,
- 5. The compound of claim 1, wherein A is H, 4-MeO—Ph—(CH2), NH2, CH2CH═CH2, CH2CH(OH)CH2OH, CH2C(═O)H, CH2-isoxazole, (CH2)NH2, (CH2)NHBoc, CH═CHPh, (C═O)H, CH2OH, CH2OCH3, (C═O)Me, (C═O)Et, methyl, ethyl, isopropyl, CH2CF3, HN(C═O)Me, SO2Me, SO2Ph, PhO, PhNH, or 4-MeO—PhNH.
- 6. The compound of claim 1, wherein Y is N, W is C, U is C, and V is N.
- 7. The compound of claim 1, wherein Y is N, W is C, U is N and V is C.
- 8. The compound of claim 1, wherein Y is C, W is N, U is C and V is C.
- 9. The compound of claim 1, wherein Y is C, W is O, U is C and V is C.
- 10. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula
- 11. The compound of claim 10, where X is O.
- 12. The compound of claim 10, where X is S.
- 13. The compound of claim 10, where X is NR7.
- 14. The compound of claim 10, where X is C═O.
- 15. The compound of claim 10, where X is CHR7.
- 16. The compound of claim 10, where X is C═NOR1.
- 17. The compound of claim 10, where X is C═CHR1.
- 18. The compound of claim 10, where X is CHOR1.
- 19. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula
- 20. A method of treating or preventing a p38-mediated condition, comprising administering an amount of a compound effective to treat or prevent said p38-mediated condition or a pharmaceutical composition comprising said compound, to a human or animal in need thereof, wherein the compound has the Formula
- 22. The method of claim 20, wherein Y is N, W is C, U is C, and V is N.
- 23. The method of claim 20, wherein Y is N, W is C, U is N and V is C.
- 24. The method of claim 20, wherein Y is C, W is N, U is C and V is C.
- 25. The method of claim 20, wherein Y is C, W is O, U is C and V is C.
- 26. The method of claim 20, wherein said p38-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, prolixferative disorder, infectious disease, viral disease or neurodegenerative disease.
- 27. A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula:
- 28. The compound of claim 27, wherein W is CH2 and Y is NR2.
- 29. The compound of claim 27, wherein G, J, K and T are CRz.
- 30. The compound of claim 27, wherein X is NH, S, or O.
- 31. The compound of claim 27, wherein Rx is CH2 and Q is —NHCO—.
- 32. The compound of claim 31, wherein Ry isopropyl or
- 33. The compound of claim 27, wherein Rx is CH2 and Q is —NR8CONH—.
- 34. The compound of claim 33, wherein Ry is
- 35. A composition comprising a compound of claim 27 and a pharmaceutically acceptable carrier.
- 36. A method of treating or preventing a p38-mediated condition in a human or animal, comprising administering to said human or animal a compound of claim 27 in an amount effective to treat or prevent said p38-mediated condition or a pharmaceutical composition comprising said compound.
- 37. The method of claim 36, wherein said p38-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part (CIP) of Ser. No. 10/688,849 filed Oct. 15, 2003, which is a CIP of Ser. No. 10/378,164 filed Mar. 3, 2003, which are incorporated in their entirety herein by this reference.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10688849 |
Oct 2003 |
US |
Child |
10788044 |
Feb 2004 |
US |
Parent |
10378164 |
Mar 2003 |
US |
Child |
10688849 |
Oct 2003 |
US |